Abstract
to fulfil increased omega-3 fatty acids need during pregnancy" (ID 539), "skin and digestive tract epithelial cells maintenance" (ID 525), enhancement of mood (ID 536), "membranes cell structure" (ID 4295), "anti-inflammatory action" (ID 4688) and maintenance of normal blood LDL-cholesterol concentrations ( EFSA Journal 2011;9(4):2078 in relation to docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and brain, eye and nerve development, maintenance of normal brain function, maintenance of normal vision, maintenance of normal cardiac function, "maternal health; pregnancy and nursing", "skin and digestive tract epithelial cells maintenance", enhancement of mood, "to fulfil increased omega-3 fatty acids need during pregnancy", "membranes cell structure", "anti-inflammatory action" and maintenance of normal blood LDL-cholesterol concentrations. The scientific substantiation is based on the information provided by the Member States in the consolidated list of Article 13 health claims and references that EFSA has received from Member States or directly from stakeholders. The food constituent that is the subject of the health claims is long-chain n-3 polyunsaturated fatty acids (n-3 LCPUFAs), namely docosahexaenoic acid (DHA) in combination with eicosapentaenoic acid (EPA). The Panel considers that DHA and EPA are sufficiently characterised.
Showing the abstract — retrieve the full paper via the Exa API.